Strategic asset exit Sprint Bioscience recently sold a cancer program, TREX1, to Gilead Sciences for $414 million, underscoring strong asset value and willingness to engage in licensing or divestment with large pharma. This signals a readiness to pursue deal-driven partnerships around early-stage oncology programs, offering potential for in-licensing, co-development, or milestone-based collaborations with Sprint as the asset owner.

Inflammation expansion A collaboration with Experimental Drug Development Centre to expand the MASH program into inflammatory diseases demonstrates Sprint's capability to adapt oncology programs for other indications and pursue cross-indication partnerships. Sales opportunities include sponsored research, co-development, or licensing deals around MASH and related inflammatory targets, leveraging Sprint's translational and discovery strengths.

AML opportunity Sprint launched a drug development program for acute myeloid leukemia in 2024 and has prior AML target work. This positions Sprint to attract collaborations with AML-focused companies seeking novel inhibitors, enabling joint development, licensing, or access to Sprint's early-stage assets and platform capabilities.

Licensing history Past licensing collaboration with Day One Biopharmaceuticals in 2023 for the VRK1 program indicates a track record of productive partnerships and licensing deals. This history can be used to approach mid-size biotech and pharma players for new partnerships on other programs or to re-engage on additional programs, including potential licensing of Sprint's discovery platform.

Lean European partner With 11-50 employees and EU operations, Sprint can act as a nimble, cost-efficient partner for early development needs. Sales opportunities include offering end-to-end preclinical and IND-enabling services, collaborative research, or co-development agreements that leverage Sprint's early-stage drug discovery strengths while outsourcing scale to client CRO/CMO networks.